PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

AUC-guided Bayesian vancomycin dosing improves targets, renal signal unconfirmed

vancomycinglycopeptidesmodel-informed precision dosingBayesian AUC dosingacute kidney injuryMRSAtherapeutic drug monitoringcritically illpharmacokineticspre-post study Pharmacokinetics / TDM

Background Information

Bayesian AUC dosing raised target attainment and cut supratherapeutic levels, but the AKI benefit vanished after adjustment.

Vancomycin is crucial for treating gram-positive infections but can cause acute kidney injury (AKI); optimizing dosing may improve safety. Model-informed AUC-based dosing reduced AKI incidence from 27.8% to 14%, and increased target attainment to 70.2% from 55.1%. The study suggests that AUC24-guided dosing can enhance vancomycin safety and efficacy, warranting broader implementation despite limited MRSA prevalence. AUC24-based vancomycin dosing improves safety and target attainment in critically ill patients.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Gundlach L, Kunkel M, Scherf-Clavel O, Surat G

Citation: Gundlach L, Kunkel M, Scherf-Clavel O, et al. Model-informed AUC-guided dosing for parenteral vancomycin in critically ill patients: impact on target attainment and renal safety - a pre-post intervention study. BMC pharmacology & toxicology. 2026;27(1). doi:10.1186/s40360-026-01224-x

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.